Browse 91 market data tables and 30 figures spread through 148 pages and in-depth TOC on "Human Microbiome Market"
https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html
Early buyers will receive 10% customization on this report.
The human microbiome market is expected to reach USD 899.1 Million by 2025 from USD 506.5 Million in 2022 growing at a CAGR of 21.1% during the forecast period (2022–2025).
The human microbiome market is segmented on the basis of application, disease, product, and region. Also, the human microbiome research spending market is broadly segmented by product and technology.
Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human microbiome market.
Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownload.asp?id=37621904
On the basis of disease, the human microbiome market comprises of obesity, diabetes, autoimmune disorders, acute diarrhea, cancer, mental disorders, and other diseases. In 2022, the acute diarrhea segment is expected to account for the largest share and is estimated to grow at the highest CAGR during the forecast period (2022–2025).
On the basis of product, the human microbiome research spending market is characterized into instruments and consumables. The instruments segment is further divided into laboratory instruments and analyzers, while, the consumables segment is further bifurcated into kits and reagents. The consumables segment is estimated to grow at the highest CAGR during the forecast period (2016–2021) owing to the repeated purchases of consumables as compared to instruments.
On the basis of technology, the human microbiome research spending market is divided into cell culture technology, high-throughput technology, omics technology, and computational tools. The cell culture technology segment is expected to account for the largest share of the global human microbiome research spending technology market in 2016. The large share can be attributed to the increasing R&D initiatives in the field of human microbiome.
Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this region can be attributed to its significant presence in the probiotics and prebiotics fields and the acceptance of these products by its population.
Get the Sample Pages@
https://www.marketsandmarkets.com/requestsample.asp?id=37621904
A number of factors such as the rising incidence of cardiovascular disease, increasing awareness about the need for diagnostic and preventive care, and technological advancement are driving the growth of this market. In developed regions like North America, the human microbiome market, in terms of value, is expected to be smaller as compared to Europe, owing to the slower acceptance of microbiome products in a number of countries in this region.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel (U.S.), and Merck (U.S.).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
